FIV gp36 Inhibitors
FIV gp36 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the glycoprotein 36 (gp36) found on the surface of the feline immunodeficiency virus (FIV). Gp36 plays a crucial role in the viral fusion process by facilitating the merger of the viral membrane with the host cell membrane, allowing viral entry into the host cell. By interfering with this fusion process, FIV gp36 inhibitors prevent the virus from successfully infiltrating host cells, thereby blocking one of the essential steps in the viral replication cycle. These inhibitors typically achieve this by binding to the helical regions of the gp36 protein, altering its structural conformation and disrupting its ability to mediate membrane fusion.
Structurally, FIV gp36 inhibitors are diverse, with compounds often designed to mimic the viral protein's helical regions or to interact directly with the key residues involved in the fusion process. Some inhibitors function by stabilizing a pre-fusion conformation of gp36, preventing the conformational changes necessary for viral fusion. This disruption can be achieved through a variety of mechanisms, including small molecule interactions or larger macromolecular agents that hinder the fusion core from forming. These inhibitors are the result of extensive studies into the molecular mechanisms of viral entry, leveraging detailed structural analyses of the gp36 protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide could hypothetically suppress global protein synthesis in host cells, thereby indirectly leading to a decrease in FIV gp36 levels due to the inhibition of translational processes. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
This compound might intercalate into DNA, theoretically leading to a cessation of viral RNA transcription and a consequent reduction in gp36 protein synthesis. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
Ribavirin may induce lethal mutagenesis during viral RNA replication, which could result in a dysfunctional gp36 protein and thus a reduction in functional gp36 expression. | ||||||
3′-Azido-3′-deoxythymidine | 30516-87-1 | sc-203319 | 10 mg | $60.00 | 2 | |
3′-Azido-3′-deoxythymidine may be incorporated into the FIV DNA by the viral reverse transcriptase, resulting in premature chain termination and a potential decrease in viral gp36 protein levels. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine might concentrate within endosomes and lysosomes, leading to an increase in pH that could conceivably impede the early stages of FIV replication, thereby reducing gp36 protein expression. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
By targeting ribonucleotide reductase, Hydroxyurea could deplete the pool of deoxynucleotides necessary for FIV DNA synthesis, potentially downregulating gp36 protein levels. | ||||||
Acyclovir | 59277-89-3 | sc-202906 sc-202906A | 50 mg 500 mg | $147.00 $922.00 | 2 | |
Acyclovir might, in a speculative scenario, be triphosphorylated by cellular enzymes and then selectively inhibit viral DNA polymerase, potentially leading to a decrease in gp36 protein synthesis. | ||||||
Tenofovir | 147127-20-6 | sc-204335 sc-204335A | 10 mg 50 mg | $154.00 $633.00 | 11 | |
If Tenofovir were to exhibit activity against FIV, it could hypothetically terminate the viral DNA chain elongation, which would result in a lower production of gp36 protein. | ||||||
Lopinavir | 192725-17-0 | sc-207831 | 10 mg | $129.00 | 6 | |
Lopinavir, though typically an HIV protease inhibitor, could conceivably inhibit a similar protease in FIV, leading to improper processing of viral proteins and a subsequent decrease in gp36 levels. | ||||||
Raltegravir | 518048-05-0 | sc-364600 sc-364600A sc-364600B sc-364600C sc-364600D | 5 mg 50 mg 100 mg 500 mg 1 g | $100.00 $821.00 $1229.00 $2861.00 $4085.00 | 21 | |
Raltegravir may, in theory, inhibit FIV integrase, which would prevent the integration of the viral DNA into the host genome, potentially leading to a downregulation of gp36 protein expression. | ||||||